RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting

被引：0

作者：

Paz-Ares, L. ^{[1
]}

Spigel, D. R. ^{[2
]}

Chen, Y. ^{[3
]}

Jove, M. ^{[4
]}

Juan-Vidal, O. ^{[5
]}

Rich, P. ^{[6
]}

Hayes, T. ^{[7
]}

Gutierrez Calderon, V. ^{[8
]}

Caro, R. B. ^{[9
]}

Navarro Mendivil, A. ^{[10
]}

Dowlati, A. ^{[11
]}

Zhang, B. ^{[12
]}

Moore, Y. ^{[12
]}

Wang, T. ^{[12
]}

Kokhreidze, J. ^{[12
]}

Ponce, S. ^{[1
]}

Bunn, P. ^{[13
,14
]}

机构：

[1] Hosp Univ 12 Octubre, Madrid, Spain

[2] Sarah Cannon Res Inst, Nashville, AL USA

[3] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA

[4] Inst Catala Oncol, Barcelona, Spain

[5] Hosp Univ & Politecn La Fe, Valencia, Spain

[6] Canc Treatment Ctr Amer, Newnan, GA USA

[7] South West Healthcare, Warrnambool, Vic, Australia

[8] Hosp Reg Univ Malaga, Malaga, Spain

[9] Hosp Univ Virgen Del Rocio, Inst Biomed Sevilla, Seville, Spain

[10] 4 Hosp Univ Vall Hebron, Barcelona, Spain

[11] Case Western Reserve Univ, Cleveland, OH 44106 USA

[12] Ipsen, Cambridge, MA USA

[13] Canc Ctr, Denver, CO USA

[14] Dept Med, Denver, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

liposomal irinotecan; small-cell lung cancer; RESILIENT;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P48.14

引用

页码：S505 / S505

页数：1